You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

c-Met Overexpressing Non-Small Cell Lung Cancer

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

NSCLC Trial (Telisotuzumab Vedotin, Osimertinib, Cisplatin)

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • Telisotuzumab Vedotin
  • +4 more
  • (no location specified)
Oct 17, 2023

Lung Non-Small Cell Carcinoma Trial (Amivantamab, Biospecimen Collection, Computed Tomography)

Not yet recruiting
  • Lung Non-Small Cell Carcinoma
  • Amivantamab
  • +3 more
  • (no location specified)
Oct 30, 2023

NSCLC Trial in Guangzhou (PLB1001)

Active, not recruiting
  • Non-small Cell Lung Cancer
  • Guangzhou, Guangdong, China
    Guangdong Provincial People's Hospital
Aug 15, 2023

Non-squamous Non-small-cell Lung Cancer, Stage IV NSCLC, ROS1 Gene Rearrangement Trial in Toronto (Crizotinib)

Recruiting
  • Non-squamous Non-small-cell Lung Cancer
  • +4 more
  • Toronto, Ontario, Canada
    Princess Margaret Cancer Centre
Jan 8, 2023

Specific Protein Overexpression in Adult Non-Small Cell Lung

Not yet recruiting
  • Non Small Cell Lung Cancer
    • (no location specified)
    Sep 29, 2023

    Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 Trial (procedure, biological, drug)

    Not yet recruiting
    • Recurrent Lung Non-Small Cell Carcinoma
    • Stage IV Lung Cancer AJCC v8
    • Biospecimen Collection
    • +5 more
    • (no location specified)
    Sep 7, 2023

    NSCLC Trial in Houston (Amivantamab, Tepotinib)

    Not yet recruiting
    • Non-small Cell Lung Cancer
    • Houston, Texas
      MD Anderson Cancer Center
    Oct 9, 2023

    NSCLC?EGFR Sensitive Mutation Trial in Bengbu, Changsha, Shanghai (MCLA-129: 1500mg or 2000mg IV Q2W, Befotertinib: 75 mg or 100

    Not yet recruiting
    • Non-Small Cell Lung Cancer、EGFR Sensitive Mutation
    • MCLA-129: 1500mg or 2000mg IV Q2W
    • Befotertinib: 75 mg or 100 mg Po QD
    • Bengbu, Anhui, China
    • +2 more
    Aug 28, 2023

    Metastatic Non Small Cell Lung Cancer Trial in Raleigh (C-TIL051)

    Not yet recruiting
    • Metastatic Non Small Cell Lung Cancer
    • C-TIL051
    • Raleigh, North Carolina
      Duke Cancer Institute
    Jan 6, 2023

    Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer Trial in San Francisco (Capmatinib, Trametinib)

    Recruiting
    • Metastatic Lung Non-Small Cell Carcinoma
    • Stage IV Lung Cancer
    • San Francisco, California
      University of California San Francisco
    Aug 15, 2022

    NSCLC Metastatic Trial in Seoul (Lazertinib, Tepotinib)

    Not yet recruiting
    • Non-Small Cell Lung Cancer Metastatic
    • Seoul, Gangnam-gu, Korea, Republic of
      Samsung Medical Center
    Oct 27, 2023

    Advanced Cancer, Non Small Cell Lung Cancer Trial (Tepotinib, Pembrolizumab)

    Not yet recruiting
    • Advanced Cancer
    • Non Small Cell Lung Cancer
    • (no location specified)
    Mar 28, 2023

    NSCLC (NSCLC) Trial in China (Capmatinib)

    Recruiting
    • Non-Small Cell Lung Cancer (NSCLC)
    • Xiamen, Fujian, China
    • +18 more
    Jan 27, 2023

    Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 Trial (procedure, drug, biological)

    Not yet recruiting
    • Recurrent Lung Non-Small Cell Carcinoma
    • Stage IV Lung Cancer AJCC v8
    • Biospecimen Collection
    • +5 more
    • (no location specified)
    Nov 30, 2022

    Advanced NSCLC With KRAS G12C Mutation Trial in New York (Sotorasib, Ladarixin)

    Not yet recruiting
    • Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation
    • New York, New York
      NYU Langone Health
    Apr 4, 2023

    Advanced NSCLC With KRAS G12C Mutation Trial in New York (Sotorasib, Ladarixin)

    Not yet recruiting
    • Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation
    • New York, New York
      NYU Langone Health
    Apr 4, 2023

    Crizotinb or Standard Chemotherapy in Met Exon 14 Skipping

    Recruiting
    • Non-small Cell Lung Cancer
      • Changsha, Hunan, China
        Yongchang Zhang
      Mar 1, 2022

      Lung Cancer Trial (Ascorbic acid, Normal Saline)

      Not yet recruiting
      • Lung Cancer
      • Ascorbic acid
      • Normal Saline
      • (no location specified)
      May 8, 2023

      Double-dose Furmonertinib in Treatment of Slow

      Not yet recruiting
      • Non Small Cell Lung Cancer
      • +3 more
      • (no location specified)
      Oct 31, 2023

      NSCLC Trial in Busan (GDC-6036, Pembrolizumab)

      Recruiting
      • Non-Small Cell Lung Cancer
      • Busan, Korea, Republic of
        Pusan National University Hospital
      Apr 3, 2023

      NSCLC Trial in Guangzhou (Savolitinib, Docetaxel)

      Not yet recruiting
      • Non-small Cell Lung Cancer
      • Guangzhou, Guangdong, China
        Department of Thoracic Surgery and Oncology, The First Affiliate
      Mar 17, 2023

      NSCLC Trial in Shanghai

      Not yet recruiting
      • Non-small Cell Lung Cancer
        • Shanghai, Shanghai, China
          Shanghai Pulmonary Hospital
        Jul 20, 2023

        NSCLC Trial in Worldwide (Osimertinib + Savolitinib, Savolitinib + Placebo)

        Active, not recruiting
        • Non-Small Cell Lung Cancer
        • Osimertinib + Savolitinib
        • Savolitinib + Placebo
        • Duarte, California
        • +20 more
        Dec 2, 2022

        NSCLC, EGFR Gene Mutation, EGFR-TKI Resistant Mutation Trial (Nintedanib, gefitinib, erlotinib, afatinib)

        Not yet recruiting
        • Non-small Cell Lung Cancer
        • +2 more
        • Nintedanib, gefitinib, erlotinib, afatinib
        • (no location specified)
        Oct 2, 2023

        NSCLC, Neoadjuvant Therapy, Radiotherapy Trial in Yangzhou (drug, radiation, other)

        Recruiting
        • Non-small Cell Lung Cancer
        • +3 more
        • Yangzhou, Jiangsu, China
          People's hospital of northern jiangsu
        Sep 26, 2023